Junio Dort

University of Ottawa — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index635citations41works8.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Muscle Physiology and Disorders(14), Cancer-related gene regulation(11), Muscle metabolism and nutrition(9), CAR-T cell therapy research(9), Adipose Tissue and Metabolism(8)

Publications41 total

Bioactive lipid mediator class switching regulates myogenic cell progression and muscle regeneration
Nature Communications·2025· 7 citedOpen Access
Long-term effect of Resolvin-D2 on Duchenne muscular dystrophy
2025Open Access
Factors associated with COVID-19 vaccine confidence among Arab, Asian, Black, Indigenous, and White individuals in Canada: Latent profile analyses
Vaccine·2025· 4 citedOpen Access
Transcriptomic and lipidomic profiling reveals distinct bioactive lipid signatures in slow and fast muscles and highlights the role of resolvin‐ <scp>D2</scp> in fiber type determination during myogenesis
The FASEB Journal·2024· 5 citedOpen Access
Rates and Factors Related to COVID‐19 Vaccine Uptake in Racialized and Indigenous Individuals in Canada: The Deleterious Effect of Experience of Racial Discrimination
Journal of Medical Virology·2024· 14 citedOpen Access
Apelin stimulation of the vascular skeletal muscle stem cell niche enhances endogenous repair in dystrophic mice
Science Translational Medicine·2024· 18 cited
Gpr18 agonist dampens inflammation, enhances myogenesis, and restores muscle function in models of Duchenne muscular dystrophy
Frontiers in Cell and Developmental Biology·2023· 16 citedOpen Access
Decreased dystrophin expression and elevated dystrophin-targeting miRNAs in anti-HMGCR immune-mediated necrotizing myopathy
Acta Neuropathologica·2023· 4 cited
<i>N</i> -acetylneuraminate pyruvate lyase controls sialylation of muscle glycoproteins essential for muscle regeneration and function
Science Advances·2023· 14 citedOpen Access
Inhibition of type I PRMTs reforms muscle stem cell identity enhancing their therapeutic capacity
eLife·2023Open Access
Author Response: Inhibition of type I PRMTs reforms muscle stem cell identity enhancing their therapeutic capacity
2023Open Access
Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Author Response: Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Reviewer #1 (Public Review): Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Reviewer #3 (Public Review): Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Inhibition of type I PRMTs reforms muscle stem cell identity enhancing their therapeutic capacity
eLife·2023· 3 citedOpen Access
Reviewer #2 (Public Review): Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Author Response: Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Nicolas A. Dumont(25), Émilie Heckel(12), Jean‐Sébastien Joyal(12), Claudia Dominici(11), Ioannis Ragoussis(11), Stéphane Richard(11), Zakaria Orfi(8), Yu Chang Wang(8), Hélène Jacques(7), Paul Fabre(6), Thomas Molina(6), Nadine Leblanc(6), Oscar D. Villarreal(6), Claude H. Côté(5), Oscar Villareal(5), Benjamin Ellezam(4), Colin Crist(4), Karine Greffard(3), Ornella Pellerito(3), Jean‐François Bilodeau(3)